NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free CANF Stock Alerts $1.96 +0.02 (+0.81%) (As of 03:01 PM ET) Add Compare Share Share Today's Range$1.91▼$1.9750-Day Range$1.94▼$2.4052-Week Range$1.71▼$3.33Volume9,252 shsAverage Volume19,134 shsMarket Capitalization$6.92 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Get Can-Fite BioPharma alerts: Email Address Can-Fite BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside673.2% Upside$15.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.45 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCan-Fite BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCan-Fite BioPharma has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CANF. Previous Next 0.0 Dividend Strength Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CANF. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by InstitutionsOnly 21.00% of the stock of Can-Fite BioPharma is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Can-Fite BioPharma Stock (NYSE:CANF)Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Read More CANF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CANF Stock News HeadlinesApril 25, 2024 | businesswire.comLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalApril 22, 2024 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.comApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 15, 2024 | businesswire.comCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHApril 3, 2024 | businesswire.comCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsMarch 28, 2024 | finanznachrichten.deCan-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical UpdateMarch 11, 2024 | businesswire.comNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceMarch 1, 2024 | investing.comCan-Fite secures Canadian patent for liver disease drugApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 28, 2024 | businesswire.comCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaFebruary 24, 2024 | wsj.comHistorical PricesFebruary 22, 2024 | finance.yahoo.comCan-Fite BioPharma Ltd. (CANF)February 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical ProspectsJanuary 30, 2024 | investing.comCan Fite Biopharma Ltd (CANF)January 30, 2024 | investing.comCan Fite Biopharma Ltd ADR (CANF)January 30, 2024 | finance.yahoo.comCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer IndicationJanuary 29, 2024 | finance.yahoo.comCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis StudyDecember 20, 2023 | finance.yahoo.comThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human StudiesDecember 18, 2023 | markets.businessinsider.comCan-Fite Reports FDA Positive Response To Its Psoriasis Pediatric Plan - Quick FactsDecember 18, 2023 | finance.yahoo.comCan-Fite Received FDA Positive Response to Psoriasis Pediatric PlanDecember 4, 2023 | finance.yahoo.comCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical DevelopmentNovember 30, 2023 | finance.yahoo.comCan-Fite Reports Third Quarter 2023 Financial Results and Clinical UpdateNovember 21, 2023 | msn.comWhy Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?November 21, 2023 | finance.yahoo.comCan-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross ProceedsNovember 21, 2023 | finance.yahoo.comCan-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with NamodenosonNovember 1, 2023 | finance.yahoo.comCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on TrackOctober 30, 2023 | finance.yahoo.comCan-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock NowSee More Headlines Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:CANF CUSIPN/A CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+661.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,630,000.00 Net Margins-1,027.46% Pretax Margin-1,027.46% Return on Equity-113.75% Return on Assets-69.91% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.90 Sales & Book Value Annual Sales$740,000.00 Price / Sales9.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.12Miscellaneous Outstanding Shares3,540,000Free Float3,512,000Market Cap$6.97 million OptionableNot Optionable Beta1.53 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Pnina Fishman Ph.D. (Age 76)Founder, Chief Scientific Officer & Executive Chairperson Comp: $644kMr. Motti Farbstein (Age 60)CEO & Chief Operating and Financial Officer Comp: $414kDr. Sari Fishman Ph.D. (Age 52)Vice President of Business Development Comp: $325kDr. Ilan Cohn Ph.D. (Age 70)Co-Founder & Director Dr. Stephen A. Harrison FACPM.D., Member of Clinical Advisory Board & Consulting Chief Medical OfficerKey CompetitorsTenax TherapeuticsNASDAQ:TENXClever LeavesNASDAQ:CLVRPulmatrixNASDAQ:PULMHillstream BioPharmaNASDAQ:HILSPasithea TherapeuticsNASDAQ:KTTAView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 154,363 shares on 2/13/2024Ownership: 4.361%View All Institutional Transactions CANF Stock Analysis - Frequently Asked Questions Should I buy or sell Can-Fite BioPharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CANF shares. View CANF analyst ratings or view top-rated stocks. What is Can-Fite BioPharma's stock price target for 2024? 1 analysts have issued twelve-month target prices for Can-Fite BioPharma's shares. Their CANF share price targets range from $12.00 to $18.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 673.2% from the stock's current price. View analysts price targets for CANF or view top-rated stocks among Wall Street analysts. How have CANF shares performed in 2024? Can-Fite BioPharma's stock was trading at $2.20 at the start of the year. Since then, CANF shares have decreased by 11.8% and is now trading at $1.94. View the best growth stocks for 2024 here. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.04. The company earned $0.16 million during the quarter, compared to analyst estimates of $0.20 million. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 113.75% and a negative net margin of 1,027.46%. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma's stock reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CANF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
